"Pteridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds based on pyrazino[2,3-d]pyrimidine which is a pyrimidine fused to a pyrazine, containing four NITROGEN atoms.
| Descriptor ID |
D011621
|
| MeSH Number(s) |
D03.633.100.733
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pteridines".
Below are MeSH descriptors whose meaning is more specific than "Pteridines".
This graph shows the total number of publications written about "Pteridines" by people in this website by year, and whether "Pteridines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pteridines" by people in Profiles.
-
Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. Int J Hematol. 2021 Jan; 113(1):92-99.
-
Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia. Mol Cancer Ther. 2019 09; 18(9):1615-1627.
-
Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis. EMBO Mol Med. 2019 05; 11(5).
-
A Novel Method for Quantifying Total Thoracic Tumor Burden in Mice. Neoplasia. 2018 10; 20(10):975-984.
-
Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer. Oncogene. 2018 04; 37(17):2251-2269.
-
Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Lett. 2017 04 28; 392:71-82.
-
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Oncotarget. 2016 Jul 26; 7(30):47998-48010.
-
Novel PKC-? to p47 phox interaction is necessary for transformation from blebbishields. Sci Rep. 2016 Apr 04; 6:23965.
-
Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clin Cancer Res. 2016 Apr 01; 22(7):1674-1686.
-
Stromal TGF-? signaling induces AR activation in prostate cancer. Oncotarget. 2014 Nov 15; 5(21):10854-69.